Laboratorios Farmaceuticos Rovi SA 2019 SR
The report highlights ROVI's 2019 performance, focusing on its leadership in low-molecular-weight heparins and its integrated pharmaceutical business model. Key achievements include the conclusion of clinical studies for Risperidone ISM and the expansion of its enoxaparin biosimilar into new markets. The company reported a 26% increase in operating revenue and a 7% growth in its workforce, reaching 1,310 employees. Sustainability efforts were centered on ethical management, environmental protection through ISO 14001 certifications, and social commitment via partnerships with various NGOs and foundations.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2019
Type: SR
Pages: 90
Back to company
Laboratorios Farmaceuticos Rovi SA
CSR Report
The report highlights ROVI's 2019 performance, focusing on its leadership in low-molecular-weight heparins and its integrated pharmaceutical business model. Key achievements include the conclusion of clinical studies for Risperidone ISM and the expansion of its enoxaparin biosimilar into new markets. The company reported a 26% increase in operating revenue and a 7% growth in its workforce, reaching 1,310 employees. Sustainability efforts were centered on ethical management, environmental protection through ISO 14001 certifications, and social commitment via partnerships with various NGOs and foundations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees